Scarica l'app Stockscreener
1.33
1.48%
-0.02
Dopo l'orario di chiusura:
1.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
Heron Therapeutics Adopts Tax Benefit Preservation Plan - TipRanks
Heron Therapeutics Adopts Rights Plan to Protect Tax Benefits - MarketScreener
Strategic Tax Planning as a Catalyst for Shareholder Value: Heron Therapeutics' Section 382 Rights Plan - AInvest
Heron Therapeutics adopts tax benefits plan to protect $1.37 billion in NOLs - Investing.com Nigeria
$1.37 Billion Tax Asset Protection: Heron Therapeutics Adopts Strategic Rights Plan to Preserve NOLs - Stock Titan
XTX Topco Ltd Sells 213,080 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Insider Buying: Heron Therapeutics, Inc. (NASDAQ:HRTX) Major Shareholder Acquires 2,387,225 Shares of Stock - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Announces Quarterly Earnings Results - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Director Purchases $2,649,819.00 in Stock - MarketBeat
Heron Therapeutics Signs Agreement with Patheon - MSN
Heron Therapeutics’ Earnings Call Highlights Growth and Strategy - TipRanks
Informed Momentum Co LLC Acquires New Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Needham & Company LLC Cuts Heron Therapeutics (NASDAQ:HRTX) Price Target to $3.00 - MarketBeat
Heron Therapeutics Strengthens Financial Position with Refinancing - MSN
Heron Therapeutics (NASDAQ:HRTX) Lowered to Hold Rating by Wall Street Zen - MarketBeat
Warner Bros Discovery Director Buys $3.55M Worth of WBD Shares, Heron Therapeutics Director Purchases $2.65M Worth of HRTX Shares - AInvest
Heron Therapeutics Soars 13.74% on Insider Buying, Strategic Moves - AInvest
Rubric Capital and Director Morgan Make Significant Investments in Heron Therapeutics - AInvest
Heron Therapeutics Strengthens Financial Position with Refinancing and Board Changes - AInvest
Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m By Investing.com - Investing.com Nigeria
Rubric capital buys Heron Therapeutics (HRTX) shares worth $3.5m - Investing.com India
Heron Therapeutics enters board agreement and completes refinancing transactions By Investing.com - Investing.com Nigeria
Heron Therapeutics: Insider Confidence and Strategic Entry Points in a Volatile Market - AInvest
Heron Therapeutics enters board agreement and completes refinancing transactions - Investing.com
Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher - Investing.com
Heron Therapeutics Convertible Notes - Leerink Partners
Heron Therapeutics Senior Credit Facility - Leerink Partners
Heron Therapeutics Q2 2025 Earnings Call Transcript Released - AInvest
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Heron Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Heron Therapeutics announces capital restructuring to support growth - MSN
Heron Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Jefferies Financial Group Inc. Buys Shares of 322,600 Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Heron Therapeutics Announces Strategic Financial Initiatives - The Globe and Mail
Heron Therapeutics 2025 Q2 Earnings Record Net Income and Revenue Growth - AInvest
Heron Therapeutics' Q2 Earnings Miss: A Misunderstood Catalyst for Long-Term Growth? - AInvest
Heron Therapeutics' Q2 2025 Earnings: Strategic Momentum Outpaces Short-Term Setbacks - AInvest
Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
TD Asset Management Inc Acquires New Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Heron Therapeutics Reports Strong Q2 2025 Results - TipRanks
Heron Therapeutics: Needham Adjusts Price Target to $3.00 - AInvest
Heron Therapeutics Raises EBITDA Guidance to $9M-$13M for 2025 Amid Restructuring and ZYNRELEF J-code Milestone - AInvest
Heron Therapeutics HRTX Q2 2025 Earnings Preview Upside Potential Amid Product Expansion - AInvest
Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 - The Malaysian Reserve
Heron Therapeutics' Q2 2025 Performance and Strategic Realignments: A Blueprint for Long-Term Growth - AInvest
Heron Therapeutics, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics raises adjusted EBITDA guidance to $9M-$13M for 2025 amid commercial restructuring and ZYNRELEF J-code milestone - MSN
Heron Therapeutics Reschedules Q2 2025 Earnings Release and Conference Call to August 8, 2025 - AInvest
Heron Therapeutics Plummets 28%: What's Fueling the Sudden Sell-Off? - AInvest
Transcript : Heron Therapeutics, Inc., Q2 2025 Earnings Call, Aug 08, 2025 - MarketScreener
Heron Therapeutics Trims Debt And Lifts Yearly Outlook - Finimize
Earnings call transcript: Heron Therapeutics faces Q2 2025 earnings miss, stock drops - Investing.com Canada
Heron Therapeutics Tightens Its Belt And Lifts Its Outlook - Finimize
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):